Literature DB >> 32449779

Mogamulizumab-induced Mucocutaneous Lichenoid Reaction: A Case Report and Short Review.

Megan H Trager1, Donatienne de Clippelé, Caroline Ram-Wolff, Adèle de Masson, Marie-Dominique Vignon-Pennamen, Maxime Battistella, Laurence Michel, Martine Bagot, Gabor Dobos.   

Abstract

is missing (Short communication).

Entities:  

Keywords:  cutaneous T cell lymphoma; mogamulizumab; mycosis fungoides; lichenoid reaction

Mesh：

Substances：

Year:  2020        PMID： 32449779      PMCID： PMC9137358          DOI： 10.2340/00015555-3527

Source DB:  PubMed          Journal:  Acta Derm Venereol        ISSN： 0001-5555            Impact factor:   3.875


  13 in total

1.  Histologic Assessment of Lichenoid Dermatitis Observed in Patients With Advanced Malignancies on Antiprogramed Cell Death-1 (anti-PD-1) Therapy With or Without Ipilimumab.

Authors:  Shaun Chou; Shelley Ji Eun Hwang; Giuliana Carlos; Deepal Wakade; Pablo Fernandez-Penas
Journal:  Am J Dermatopathol       Date:  2017-01       Impact factor: 1.533

2.  Generalized lichen nitidus-like eruption in the setting of mogamulizumab and tremelimumab.

Authors:  Alvin W Li; Christine J Ko; Jonathan S Leventhal
Journal:  Eur J Dermatol       Date:  2017-06-01       Impact factor: 3.328

3.  Association of autoimmunity and long-term complete remission in patients with Sézary syndrome treated with mogamulizumab.

Authors:  P Bonnet; M Battistella; M Roelens; C Ram-Wolff; F Herms; L Frumholtz; J-D Bouaziz; P Brice; H Moins-Teisserenc; M Bagot; A de Masson
Journal:  Br J Dermatol       Date:  2018-11-22       Impact factor: 9.302

4.  Lichenoid mucosal reaction to rituximab.

Authors:  Michal Kuten-Shorrer; Ephraim P Hochberg; Sook-Bin Woo
Journal:  Oncologist       Date:  2014-08-28

Review 5.  Lichen striatus associated with etanercept treatment of rheumatoid arthritis.

Authors:  Viviana Lora; Jean Kanitakis; Alessandra Latini; Carlo Cota
Journal:  J Am Acad Dermatol       Date:  2014-04       Impact factor: 11.527

6.  Clinical and Histologic Features of Lichenoid Mucocutaneous Eruptions Due to Anti-Programmed Cell Death 1 and Anti-Programmed Cell Death Ligand 1 Immunotherapy.

Authors:  Veronica J Shi; Nemanja Rodic; Scott Gettinger; Jonathan S Leventhal; Julia P Neckman; Michael Girardi; Marcus Bosenberg; Jennifer N Choi
Journal:  JAMA Dermatol       Date:  2016-10-01       Impact factor: 10.282

Review 7.  The modern approach to mantle cell lymphoma.

Authors:  Simon Rule
Journal:  Hematol Oncol       Date:  2019-06       Impact factor: 5.271

8.  A dissimilar biosimilar? Lichenoid drug eruption induced by an infliximab biosimilar.

Authors:  N Gonzalez; P Patel; G Han
Journal:  Br J Dermatol       Date:  2018-02-07       Impact factor: 9.302

9.  Mogamulizumab versus vorinostat in previously treated cutaneous T-cell lymphoma (MAVORIC): an international, open-label, randomised, controlled phase 3 trial.

Authors:  Youn H Kim; Martine Bagot; Lauren Pinter-Brown; Alain H Rook; Pierluigi Porcu; Steven M Horwitz; Sean Whittaker; Yoshiki Tokura; Maarten Vermeer; Pier Luigi Zinzani; Lubomir Sokol; Stephen Morris; Ellen J Kim; Pablo L Ortiz-Romero; Herbert Eradat; Julia Scarisbrick; Athanasios Tsianakas; Craig Elmets; Stephane Dalle; David C Fisher; Ahmad Halwani; Brian Poligone; John Greer; Maria Teresa Fierro; Amit Khot; Alison J Moskowitz; Amy Musiek; Andrei Shustov; Barbara Pro; Larisa J Geskin; Karen Dwyer; Junji Moriya; Mollie Leoni; Jeffrey S Humphrey; Stacie Hudgens; Dmitri O Grebennik; Kensei Tobinai; Madeleine Duvic
Journal:  Lancet Oncol       Date:  2018-08-09       Impact factor: 41.316

10.  Diffuse lichen planus-like keratoses and clinical pseudo-progression associated with avelumab treatment for Merkel cell carcinoma, a case report.

Authors:  Michael A Cardis; Hong Jiang; Julius Strauss; James L Gulley; Isaac Brownell
Journal:  BMC Cancer       Date:  2019-06-04       Impact factor: 4.430
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.